linjc16/ctgov huggingface dataset:
Cervical Length on Pregnancy Termination

Study Overview
=================
Brief Summary
-----------------
Cervical length is used as a parameter to predict cervical insufficiency and onset of labor. However, its role in predicting abortion induction is unclear.To investigate the impact of cervical length measurement and fetal viability on second trimester pregnancy termination duration in nulliparous pregnant women.

Detailed Description
-----------------
Cervical length and fetal viability were evaluated prior to second trimester pregnancy termination due to various indications. nulliparous pregnant women through 13 and 26 gestational weeks in whom pregnancy termination was conducted within 72 hours after admission were included in the study. The subjects were grouped into two groups according to fetal viability.

Official Title
-----------------
The Impact of Fetal Viability and Cervical Length on Pregnancy Termination Outcomes in Nulliparous Second Trimester Pregnancies

Conditions
-----------------
Pregnancy Loss

Intervention / Treatment
-----------------
* Procedure: cervical length measurement


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: -Nulliparous pregnant women at 13-26 weeks of gestation Exclusion Criteria: Patients with multiple gestations, multiparous patients or patients that had uterine gynecologic surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: cervical length measurement|cervical length measurement at second trimester pregnancy termination in nulliparous pregnant women.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| cervical length measurement | cervical length measurement at second trimester pregnancy termination in nulliparous pregnant women. The measurements will be saved as a number in cm. | 2 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cervix, Length, Viability, prostaglandin, Termination
Mechanisms of Cardiac Dysfunction in HIV and the Effect of Statins: A Cardiac MRI Study

Study Overview
=================
Brief Summary
-----------------
In this study, investigators plan to test whether statins can preserve and/or improve diastolic function among asymptomatic persons with HIV who are on anti-retroviral therapy. Both myocardial fibrosis and myocardial steatosis are thought to contribute to diastolic dysfunction and eventually overt heart failure in HIV. HIV-positive participants will undergo cardiac MRI/MRS imaging studies for the evaluation of myocardial fibrosis and myocardial steatosis prior to initiation of statin or placebo therapy and then two years after initiation of statin or placebo therapy. Traditional markers of cardiovascular (CVD) risk, systemic immune activation/ inflammation, HIV-specific parameters (i.e. CD4 count), and markers of myocardial stretch/injury will be assessed in relation to cardiac MRI/MRS outcomes.

Official Title
-----------------
Mechanisms of Cardiac Dysfunction in HIV and the Effect of Statins: A Cardiac MRI Study

Conditions
-----------------
HIV Infections

Intervention / Treatment
-----------------
* Other: Cardiac MRI/MRS


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: New enrollment in the REPRIEVE Trial Exclusion Criteria: clinical diagnosis of HFpEF or HFrEF, by subject report standard contraindications to MRI procedure based on MRI Patient Procedure Screening Form - including history of severe allergy to gadolinium

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Statin group<br>HIV-infected individuals receiving statin therapy for the duration of the study | Other: Cardiac MRI/MRS<br>* whole blood, plasma, and serum<br>|
| Placebo group<br>HIV-infected individuals receiving placebo therapy for the duration of the study | Other: Cardiac MRI/MRS<br>* whole blood, plasma, and serum<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Extracellular Volume (ECV), a measure of myocardial fibrosis on Cardiac MRI |  | Two years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Diastolic function on Cardiac MRI |  | Two years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
HIV, Diastolic Dysfunction, Myocardial fibrosis, Statin
Proposal For The Development Of A Well Defined Database For Patients With Oral Bisphosphonate-Related Osteonecrosis

Study Overview
=================
Brief Summary
-----------------
In cooperation with Merck & Co, Inc. we will identify and form a database of 35 patients who have developed osteochemonecrosis of the jaws related to oral bisphosphonate use. We will study the triggers, associated medical conditions and medications, location of the lesion(s), and patient outcomes.

Detailed Description
-----------------
This study is an observational study, and not a comparative trial. The major outcome is represented by the fraction of subjects with long term healed lesions.

Official Title
-----------------
Proposal For The Development Of A Well Defined Database For Patients With Oral Bisphosphonate-Related Osteonecrosis of the Jaws (BON)

Conditions
-----------------
Osteonecrosis

Intervention / Treatment
-----------------
* Other: Observational


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Exposed bone in the oral cavity of greater than 6-8 weeks duration unresponsive to therapy Exclusion Criteria: Pregnant patients Patients less than 30 yrs of age or greater than 90 yrs of age Mentally incompetent individuals

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Observational<br>Group of patients with osteochemonecrosis related to oral bisphosphonate use | Other: Observational<br>* Group of patients with osteochemonecrosis related to oral bisphosphonate use<br>* Other names: Osteochemonecrosis;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| establish complete database and publish descriptive paper |  | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
osteonecrosis, jaws, bisphosphonate, fosamax, alendronate
Safety, Tolerability and Effectiveness of Natalizumab in Adolescents With Active Crohn's Disease

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the safety and tolerability of natalizumab in adolescents (ages 12-17) diagnosed with moderately to severely active Crohn's disease (CD). It is thought that natalizumab may stop the movement of certain cells, known as white blood cells, into bowel tissue. These cells are thought to cause damage in the bowel leading to the symptoms of Crohn's disease. Patients who complete this study may be eligible for long-term natalizumab therapy via extension protocol ELN100226-352.

Official Title
-----------------
A Phase II, International, Multicenter, Open Label Study of the Safety, Tolerability and Effectiveness of Three Intravenous Infusions of Antegren (Natalizumab) in Adolescents With Moderately to Severely Active Crohn's Disease

Conditions
-----------------
Crohn's Disease

Intervention / Treatment
-----------------
* Drug: natalizumab


Participation Criteria
=================
Eligibility Criteria
-----------------
Male and female patients, 12-17 years of age, who have at least a six-month history of Crohn's disease and who are currently experiencing moderately to severely active Crohn's disease. Females must not be breastfeeding or pregnant, and must not become pregnant during the study.

Ages Eligible for Study
-----------------
Minimum Age: 12 Years
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: natalizumab|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
To Assess Ear Blood Flow During Dialysis

Study Overview
=================
Brief Summary
-----------------
This is a prospective observational pilot study of patients under the care of the Royal Free Hospital with chronic kidney disease who have been established on regular thrice weekly haemodialysis treatments in a dialysis centre,to measure the changes in blood flow in the ear during haemodialysis.

Detailed Description
-----------------
10 patients, attending for thrice weekly outpatient haemodiafiltration shall be studied during a dialysis session using a CE marked commercially available digital otoscope capable of recording digital videos of the tympanic membrane and ear canal. Patients will receive standard clinical care and monitoring of their dialysis session, which includes recording of blood pressure and changes in haematocrit and volume status during dialysis and noting patient symptoms.

Official Title
-----------------
Pilot Study to Assess the Effects of Haemodialysis Treatments on Blood Flow to the Ear

Conditions
-----------------
Kidney Failure

Intervention / Treatment
-----------------
* Other: no intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients age 18 years and older up to 80 years Under the care of the Royal Free Hospital with chronic kidney disease and established on regular thrice weekly haemodiafiltration. Able to provide written informed consent obtained Exclusion Criteria: Patients unable to provide written informed consent Patients using hearing aids Patients who have had previous middle ear surgery Patients not fulfilling inclusion criteria

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: no intervention|observational study|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change in ear blood flow | percentage change in ear blood flow compared to initial ear blood flow | day 1 dialysis session | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change in blood pressure | change in blood pressure in mmHg compared to starting blood pressure | day 1 dialysis session | 
| change in haematocrit volume status | percentage change in haematocrit | day 1 dialysis session | 
| record of hypotensive episodes during dialysis | record of nursing interventions including reduction in ultrafiltration volume, administration of intravenous fluids. Use of distress thermometer visual analogue scale to record patient symptoms | day 1 dialysis session | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
haemodialysis, hypotension
The Impact of Vitamin D on Tuberculosis Among Koreans

Study Overview
=================
Brief Summary
-----------------
Vitamin D has been regarded to be beneficial to tuberculosis (TB) patients. The aim of this study is to elucidate the role of vitamin D deficiency in development and treatment outcomes among Korean TB patients. Furthermore, the impact of genotypes of vitamin D receptor gene on TB development will also be evaluated.

Official Title
-----------------
The Impact of Vitamin D Level and Single Nucleotide Polymorphisms of Vitamin D Receptor Gene on the Development and Treatment Response of Tuberculosis

Conditions
-----------------
Tuberculosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: older than 19 years diagnosed and treated having a tuberculosis Exclusion Criteria: positive HIV antibody

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with TB<br> | |
| People without TB<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of Vitamin D Deficiency |  | At enrollment | 
| Median 25-OHD Level |  | August 2010 to March 2011 |
ROSCAP: Reduction of Smoking in Cardiac Patients Study

Study Overview
=================
Brief Summary
-----------------
Background. The ROSCAP Study was a randomized controlled trial in heart disease patients to test the effect of a smoking reduction intervention on cigarettes per day (cpd) and biochemical and clinical indicators of tobacco exposure. .

Conditions
-----------------
Nicotine Dependence, Tobacco Dependence, Cardiac Disease

Intervention / Treatment
-----------------
* Behavioral: smoking reduction intervention (including NRT)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: smoked at least 15 cigarettes per day and had one of 11 cardiovascular disorders: history of myocardial infarction, coronary artery bypass surgery, angioplasty, stent placement, thrombolytic therapy, angina, arrhythmia, a history of cardiac arrest, greater than 50% coronary artery stenosis by angiography, ischemia on exercise tolerance testing or congestive heart failure, required to confirm that they were unwilling or uninterested in setting a stop smoking date in the next 30 days. Exclusion Criteria: 1) unstable angina within the past 2 weeks, 2) unstable psychiatric or substance use disorders or 3) contraindications to nicotine replacement therapy (including pregnancy or intention to become pregnant)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: smoking reduction intervention (including NRT)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Smoking reduction |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Smoking cessation, biomarker measures |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
tobacco, nicotine, smoking reduction
Study of Phenotype and Genotype Correlations in Patients With Contiguous Gene Deletion Syndromes

Study Overview
=================
Brief Summary
-----------------
OBJECTIVES: I. Investigate phenotype and genotype correlations in patients with Smith-Magenis syndrome (SMS) associated with del(17p11.2). II. Clinically evaluate SMS patients with unusual deletions or duplication of proximal 17p. III. Clinically evaluate patients with Williams syndrome with molecular characterization of 7q11.23. IV. Perform clinical studies of Prader-Willi, Angelman, DiGeorge, and Shprintzen syndrome patients with unique molecular findings in 15q11q13 or 22q11.2. V. Perform genotype and phenotype correlations in Prader-Willi patients, particularly those with loss of expression of only some of the imprinted transcripts in 15q11-q13. VI. Evaluate putative Angelman syndrome patients who do not have classic large deletion, uniparental disomy, or imprinting mutations, and perform molecular studies of the Angelman gene, UBE3A, and identify mutations of this gene. VII. Investigate phenotype and genotype correlations in patients with terminal deletions of chromosome 1p.

Detailed Description
-----------------
PROTOCOL OUTLINE: Patients undergo clinical, cytogenetic, and molecular studies. These include radiographic, neurologic, developmental, and 24 hour sleep studies, ophthalmologic, otolaryngologic, speech and language, and audiologic exams, echocardiogram, and renal ultrasound. Smith-Magenis patients are also evaluated with the following: urine melatonin levels during day and night hours; anthropometrics; sleep and behavioral history; and renal, immunologic, and cholesterol studies. A clinical and phenotypic map is constructed. When appropriate, parental chromosome analysis is performed.

Conditions
-----------------
Williams Syndrome, Angelman Syndrome, Prader-Willi Syndrome, Shprintzen Syndrome, Smith-Magenis Syndrome, DiGeorge Syndrome, Chromosome Abnormalities

Participation Criteria
=================
Eligibility Criteria
-----------------
PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Contiguous gene deletion syndrome, e.g.: Smith-Magenis syndrome Williams syndrome DiGeorge syndrome Shprintzen syndrome (velo-cardio-facial syndrome) Prader-Willi syndrome Angelman syndrome Deletion of chromosome 1p Patient age: Any age

Ages Eligible for Study
-----------------
Minimum Age: 0 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Angelman syndrome, DiGeorge syndrome, Prader-Willi syndrome, Shprintzen syndrome, Smith-Magenis syndrome, Williams syndrome, genetic diseases and dysmorphic syndromes, neurologic and psychiatric disorders, rare disease
Evaluation of the QuantiFERON-TB Test.

Study Overview
=================
Brief Summary
-----------------
To compare the results of the investigational test to the currently approved QuantiFERON-TB Gold In-Tube test.

Detailed Description
-----------------
To compare the specificity of the CST001 assay to the QFT Gold Test in low TB exposure risk subjects and non-tuberculosis mycobacterial infections.

Official Title
-----------------
Evaluation of the 4th Generation QuantiFERON-TB Gold Test (CST001) for the Detection of Tuberculosis Infection

Conditions
-----------------
Tuberculosis

Intervention / Treatment
-----------------
* Device: CST_001


Participation Criteria
=================
Eligibility Criteria
-----------------
Low-exposure Risk Group Inclusion Criteria: No identified risk factors for TB infection Exclusion Criteria: Age less than 18 years or greater than 80 years Identified Risk Factors For TB Infection Non-tuberculous mycobacterial infection Group Inclusion Criteria: history of nontuberculous mycobacterial disease (pulmonary or extrapulmonary) in accordance with the 2007 ATS/IDSA criteria Exclusion Criteria: Age less than 18 years or greater than 80 years Identified Risk Factors For TB Infection

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| non TB infection<br>Group tested with CST_001 | Device: CST_001<br> <br> |
| low exposure risk<br>Group tested with CST_001 | Device: CST_001<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical Specificity of the CST001 Assay as Measured by the Number of Correctly Identified Actual Negatives | To compare the clinical specificity of the CST001 assay to the QuantiFERON-TB Gold test in low TB exposure risk subjects and non TB infected subjects based on an assessment of known risk factors. These subjects had no identified risk factors of TB infection. | 1 day (At time of enrollment) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
TB, Tuberculosis